AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Mitogen Activated Protein Kinase 1, Pipeline Review, H2 2019 - Antengene Corp, Kura Oncology Inc & Kalyra Pharmaceuticals Inc - ResearchAndMarkets.com

January 20, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 20, 2020--

The “Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019” drug pipelines have been added to ResearchAndMarkets.com’s offering.

Summary

According to the recently published report ‘Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019’, Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules.

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Mitogen-activated protein kinase 1 is an enzyme encoded by the MAPK1 gene. It is involved in a variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases. Upon activation, they translocate to the nucleus of the stimulated cells, where it phosphorylates nuclear targets. It acts as a transcriptional repressor. It plays an important role in the spindle assembly checkpoint.

The report ‘Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019’ outlays comprehensive information on the Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gurqka

View source version on businesswire.com:https://www.businesswire.com/news/home/20200120005213/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/20/2020 06:29 AM/DISC: 01/20/2020 06:29 AM

http://www.businesswire.com/news/home/20200120005213/en